I am currently Professor of Cell and Molecular Biology at the University of Liverpool, which is actually my home town and continues to fascinate me. I have moved around though! After graduating in Chemistry and then a PhD in Biophysics in the UK, I did a post-doc at NIH studying membrane fusion mechanisms. I only really found my metier after moving for a second post-doc to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. This was a great environment to learn intricate cell biology techniques and remains a strong influence on how we approach our science. After establishing my own laboratory at Liverpool, we initially focused on the interplay between endosomal membrane trafficking and cell signaling. This ultimately led me to ubiquitin biology and to the deubiquitylases (DUBs). We laid down the concept that a balance between ubiquitin ligase and deubiquitylase activities determine receptor fate at the endosome. Since then we have been interested in identifying DUBs germane to oncology and neurodegeneration, with the aim of mechanistic understanding. In recent years, I have been pleased to work together with industry partners to drive the development of DUB inhibitors. I now look forward to working with Entact on the next phase of the DUB translational story — harnessing rather than inhibiting their activity.
See what Michael and their colleagues have been up to:
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Guiding a young, groundbreaking company to maturity calls for a leader who can strike the right balance between oversight and support. Victoria Richon is hoping to provide just that as the new CEO of Entact Bio, a preclinical biotech that came out of stealth in December...
Entact Bio: Victoria Richon, CEO
The language of drug development is often militaristic. Medicinal chemists build arsenals of small molecules—looking for inhibitors or “warheads” that can hit “targets” and “combat” disease. Block, eliminate, disrupt, halt. For decades, drug makers have sought “magic bullets” that can precisely destroy ...
Entact Bio launches with $81 million to enhance protein function
When proteins within the body get tagged with a molecule called ubiquitin, they are essentially marked for destruction. But they can be saved; a deubiquitinase enzyme can remove the ubiquitin, keeping the protein intact. That, at least in part, is what Entact Bio aims to do...
Biotech cofounded by Dana-Farber scientists launches with $81m for new approach to drugs
A small startup in Watertown has raised millions of dollars for early-stage research on a potentially powerful new idea that’s beginning to take hold in the biotech industry: designing drugs to enhance or prolong the function of helpful proteins that ward off disease. If successful, the approach could lead to new therapie...